ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements with these filters
Krsnaa Diagnostics informs exchanges that its RTA, KFin Technologies, will shift its corporate office effective December 1, 2026. The registered office and the company's own operations are unaffected.
Krsnaa's auditor certified upfront consideration for 16.21 lakh promoter warrants at Rs.566 each, totalling Rs.91.75 Crore issue value. Certificate confirms upfront money came directly from allottees' accounts.
Krsnaa Diagnostics secured a 15-year cash-based PPP project from the Municipal Corporation of Delhi. The contract involves establishing CT Scan and MRI facilities at three public hospitals.
Krsnaa hit ₹500 Cr H1 revenue, but heavy Rajasthan ramp-up costs and government receivable delays (₹472 Cr) are squeezing margins and PAT.
Q2 FY27 revenue INR 2,710 Mn (+32% YoY) and PAT INR 246 Mn (+3%). EBITDA margin fell to 27% from 29% on Rajasthan fixed costs.
Krsnaa Diagnostics reported record Q2 revenue of Rs 2,710 million, up 32% year on year. H1 PAT fell to Rs 411 million on Rajasthan project costs.
Krsnaa Diagnostics Ltd reported revenue from operations of ₹271 Cr (+31.6% YoY) and net profit of ₹24.6 Cr (+2.9% YoY) for Q2 FY27.
Krsnaa Diagnostics intimated that its board will meet on November 2, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. No financial figures are disclosed in this notice.
Krsnaa Diagnostics has formed a strategic AI collaboration with AZmed to integrate AI radiology solutions for enhanced operational efficiency and scalable diagnostic reporting.
Krsnaa Diagnostics Ltd submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026.
Krsnaa Diagnostics has allotted 16,21,000 convertible warrants to 2 investors at a price of Rs. 566 per warrant.
Krsnaa Diagnostics allotted 16.21 lakh convertible warrants to promoter entities at ₹566 per warrant. The company collected ₹22.94 Crore as 25% upfront subscription money.
Krsnaa Diagnostics received in-principle approval from BSE and NSE to issue 16.21 lakh convertible warrants at Rs. 566 per share to the promoter group.
Krsnaa Diagnostics Limited has appointed M/s Kirtane & Pandit LLP as Statutory Auditors for a five-year term. The appointment is effective from April 1, 2026.
Krsnaa Diagnostics Limited has appointed M/s Kirtane & Pandit LLP as its Statutory Auditor for a five-year term. The appointment was approved at the 16th Annual General Meeting.
Krsnaa Diagnostics received board approval to sell identified diagnostic equipment for an aggregate consideration of up to ₹120 crore, aiming to optimize its asset portfolio.
Krsnaa Diagnostics Limited conducted its 16th Annual General Meeting on September 28, 2026. Shareholders considered resolutions including the adoption of financial statements and a final dividend declaration.
Krsnaa Diagnostics Ltd reported the successful passing of a special resolution via postal ballot approving the issuance of up to 16,21,000 convertible warrants to promoters.
Krsnaa Diagnostics executed a 15-year concession agreement with the Punjab Government to develop and operate PET-CT diagnostic facilities at four government hospitals.